Literature DB >> 22727732

Profound impact of gut homeostasis on chemically-induced pro-tumorigenic inflammation and hepatocarcinogenesis in rats.

Hui-Lu Zhang1, Le-Xing Yu, Wen Yang, Liang Tang, Yan Lin, Han Wu, Bo Zhai, Ye-Xiong Tan, Lei Shan, Qiong Liu, Hai-Yang Chen, Rong-Yang Dai, Bi-Jun Qiu, Ya-Qin He, Chao Wang, Long-Yi Zheng, Yu-Qiong Li, Fu-Quan Wu, Zhong Li, He-Xin Yan, Hong-Yang Wang.   

Abstract

BACKGROUND & AIMS: Due to its anatomic connection, the liver is constantly exposed to gut-derived bacterial products or metabolites. Disruption of gut homeostasis is associated with many human diseases. The aim of this study was to determine the role of gut homeostasis in initiation and progression of hepatocellular carcinoma (HCC).
METHODS: Disruption of intestinal homeostasis by penicillin or dextran sulfate sodium (DSS) and its restoration by probiotics were applied in a diethylnitrosamine (DEN) model of rat hepatocarcinogenesis.
RESULTS: Patients with liver cirrhosis and HCC had significantly increased serum endotoxin levels. Chronic DEN treatment of rats was associated with an imbalance of subpopulations of the gut microflora including a significant suppression of Lactobacillus species, Bifidobacterium species and Enterococcus species as well as intestinal inflammation. Induction of enteric dysbacteriosis or intestinal inflammation by penicillin or DSS, respectively, significantly promoted tumor formation. Administration of probiotics dramatically mitigated enteric dysbacteriosis, ameliorated intestinal inflammation, and most importantly, decreased liver tumor growth and multiplicity. Interestingly, probiotics not only inhibited the translocation of endotoxin, which bears pathogen-associated molecular patterns (PAMPs) but also the activation of damage-associated molecular patterns (DAMPs) such as high-mobility group box 1 (HMGB1). As a result, the production of pro- and anti-inflammatory cytokines was skewed in favor of a reduced tumorigenic inflammation in the liver.
CONCLUSIONS: The data highlights the importance of gut homeostasis in the pathogenesis of HCC. Modulation of the gut microbiota by probiotics may represent a new avenue for therapeutic intervention to treat or prevent HCC development.
Copyright © 2012 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22727732     DOI: 10.1016/j.jhep.2012.06.011

Source DB:  PubMed          Journal:  J Hepatol        ISSN: 0168-8278            Impact factor:   25.083


  88 in total

1.  Intestinal barrier dysfunction in cirrhosis: Current concepts in pathophysiology and clinical implications.

Authors:  Georgios I Tsiaoussis; Stelios F Assimakopoulos; Athanassios C Tsamandas; Christos K Triantos; Konstantinos C Thomopoulos
Journal:  World J Hepatol       Date:  2015-08-18

Review 2.  Functional Microbiomics in Liver Transplantation: Identifying Novel Targets for Improving Allograft Outcomes.

Authors:  Michael Kriss; Elizabeth C Verna; Hugo R Rosen; Catherine A Lozupone
Journal:  Transplantation       Date:  2019-04       Impact factor: 4.939

Review 3.  Probiotics and liver disease.

Authors:  Vishal Sharma; Shashank Garg; Sourabh Aggarwal
Journal:  Perm J       Date:  2013

Review 4.  Microbiota in cancer development and treatment.

Authors:  Muhammad Hassan Raza; Kamni Gul; Abida Arshad; Naveeda Riaz; Usman Waheed; Abdul Rauf; Fahad Aldakheel; Shatha Alduraywish; Maqbool Ur Rehman; Muhammad Abdullah; Muhammad Arshad
Journal:  J Cancer Res Clin Oncol       Date:  2018-12-12       Impact factor: 4.553

Review 5.  The gut microbiota: A new potential driving force in liver cirrhosis and hepatocellular carcinoma.

Authors:  Marco Sanduzzi Zamparelli; Alba Rocco; Debora Compare; Gerardo Nardone
Journal:  United European Gastroenterol J       Date:  2017-05-08       Impact factor: 4.623

6.  Improve gut microbiome: a new horizon of cancer therapy.

Authors:  Hiroshi Fukui
Journal:  Hepatobiliary Surg Nutr       Date:  2017-12       Impact factor: 7.293

Review 7.  Demystifying the manipulation of host immunity, metabolism, and extraintestinal tumors by the gut microbiome.

Authors:  Ziying Zhang; Haosheng Tang; Peng Chen; Hui Xie; Yongguang Tao
Journal:  Signal Transduct Target Ther       Date:  2019-10-12

Review 8.  Targeted and Immune-Based Therapies for Hepatocellular Carcinoma.

Authors:  Tim F Greten; Chunwei Walter Lai; Guangfu Li; Kevin F Staveley-O'Carroll
Journal:  Gastroenterology       Date:  2018-10-01       Impact factor: 22.682

9.  p53 promotes inflammation-associated hepatocarcinogenesis by inducing HMGB1 release.

Authors:  He-Xin Yan; Hong-Ping Wu; Hui-Lu Zhang; Charles Ashton; Chang Tong; Han Wu; Qi-Jun Qian; Hong-Yang Wang; Qi-Long Ying
Journal:  J Hepatol       Date:  2013-05-25       Impact factor: 25.083

Review 10.  Role of the microenvironment in the pathogenesis and treatment of hepatocellular carcinoma.

Authors:  Virginia Hernandez-Gea; Sara Toffanin; Scott L Friedman; Josep M Llovet
Journal:  Gastroenterology       Date:  2013-01-09       Impact factor: 22.682

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.